Key facts
- PhotoniCare’s last known valuation is $43.0M.
- It has raised $19.7M across 2 recorded rounds; the latest was Seed Round ($4.6M) in Nov 2024.
- Notable investors include US National Science Foundation, MedTech Innovator, Matter (Consulting Services (B2B)), Sony Innovation Fund, Michigan Rise — 33 tracked in total.
- PhotoniCare has filed 2 Form Ds with the SEC since 2023, most recently Nov 2024 ($4.6M sold to 4 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 33 names
- ·Watchlist + deal alerts for PhotoniCare
Funding rounds
2 roundsAbout PhotoniCare
Developer of ear diagnosis devices designed to change the way physicians manage middle ear infections. The company's devices use light-based technology to see through the eardrum to directly and harmlessly visualize the middle ear and which antibiotics or surgical interventions might be needed, enabling clinicians to determine whether a patient needs antibiotics or surgical intervention.
- Sector
- Healthcare
- HQ
- Durham, NC, United States
- Founded
- 2013
- Employees
- 25
- Website
- photoni.care/
- Ownership
- Privately Held (backing)
PhotoniCare doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in PhotoniCare shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on PhotoniCare in its N-PORT filings yet. We sweep new filings monthly.